# OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)

Study · id `cardio:ct-nct07576257` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07576257](<https://clinicaltrials.gov/study/NCT07576257>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07576257

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT07576257. Randomized; no masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT07576257, source copy `cardio:ctgov-nct07576257-2026-05-08`, retrieved 2026-10-26)
- Planned start: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT07576257, source copy `cardio:ctgov-nct07576257-2026-05-08`, retrieved 2026-10-26)
- Primary completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT07576257, source copy `cardio:ctgov-nct07576257-2026-05-08`, retrieved 2026-10-26)
- Completion: 2030-06-30 (anticipated) (ClinicalTrials.gov record NCT07576257, source copy `cardio:ctgov-nct07576257-2026-05-08`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07576257-2026-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)
- Acronym: OPRA-HF Extens
- Condition: Heart Failure
- Intervention (Drug): potassium binder
- Lead sponsor: Sahlgrenska University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Sahlgrenska University Hospital (`cardio:org-sahlgrenska-university-hospital`)

## Provenance

Content hash: d4ba20e3761375fabdefd5cb05f163cfca615e6c6bbacf0c82c3d4dc45c96655
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
